What could be causing hair shedding after starting liothyronine therapy?

Hair Shedding After Starting Liothyronine

Hair shedding after starting liothyronine most likely represents iatrogenic hyperthyroidism from overtreatment, which directly triggers telogen effluvium by accelerating the hair cycle and forcing follicles prematurely into the shedding phase.

Mechanism of Thyroid Hormone-Induced Hair Loss

• Both excess and insufficient thyroid hormone levels disrupt normal hair follicle cycling and cause diffuse hair shedding (telogen effluvium). 1
• Thyroid hormones (T3 and T4) are direct regulators of human hair follicle function: they modulate keratinocyte proliferation, control anagen duration, and influence the transition between growth and resting phases. 2
• Hyperthyroidism—whether endogenous or drug-induced—accelerates the hair cycle, shortening anagen (growth phase) and pushing a larger proportion of follicles into telogen (resting/shedding phase) simultaneously. 1, 3
• Liothyronine (T3) has a rapid onset of action and produces significant serum T3 excursions when dosed once daily, with peak concentrations reaching nearly 300 ng/dL within hours of administration. 4

Assessing for Overtreatment

Check TSH, free T4, and total or free T3 within 4 weeks of starting liothyronine to confirm biochemical hyperthyroidism. 5

• A suppressed TSH (<0.1 mIU/L) with elevated free T3 confirms overt iatrogenic hyperthyroidism. 5
• Even a mildly suppressed TSH (0.1–0.45 mIU/L) with high-normal or elevated T3 indicates subclinical overtreatment, which still carries cardiovascular and metabolic risks. 6
• Approximately 20% of patients on thyroid hormone therapy become overtreated, and this overtreatment is a well-recognized cause of hair shedding. 6

Immediate Management Steps

Reduce the liothyronine dose by 5 mcg and recheck thyroid function in 4–8 weeks. 7, 6

• The FDA label for liothyronine explicitly warns that excessive doses can produce serious manifestations of toxicity, and dose adjustments should be made in 5 mcg increments at 2-week intervals. 7
• If the patient is on combination levothyroxine + liothyronine therapy, reduce or discontinue the liothyronine component first, as T3 has a shorter half-life and more pronounced pharmacodynamic effects. 4
• Target a TSH within the reference range of 0.45–4.12 mIU/L; avoid suppressing TSH below this range unless treating thyroid cancer or nodules under endocrinology guidance. 6

Expected Timeline for Hair Recovery

• Hair shedding typically begins 2–3 months after the thyroid disturbance (either hypo- or hyperthyroidism) due to the delayed telogen phase. 1, 3
• Once thyroid hormone levels are normalized, hair regrowth usually begins within 3–6 months, though full recovery may take up to 12 months. 1, 8
• Reassure the patient that this is a transient phenomenon; the FDA label notes that partial hair loss in the first months of thyroid therapy is usually temporary and recovery is the rule. 7

Differential Diagnosis: Rule Out Hypothyroidism

• Although less likely if the patient just started liothyronine, inadequate thyroid replacement can also cause hair loss. 3, 8
• Hypothyroidism-related hair loss is associated with higher TSH levels (often >10 mIU/L) and more severe shedding than hyperthyroidism. 3
• If TSH is elevated rather than suppressed, the liothyronine dose is insufficient and should be increased by 5 mcg every 2 weeks until TSH normalizes. 7, 6

Additional Considerations

• Adrenal insufficiency must be excluded before initiating or adjusting thyroid hormone therapy, as untreated hypocortisolism can be unmasked or worsened by thyroid replacement, potentially contributing to hair loss and other symptoms. 7
• If the patient is on other medications that affect thyroid hormone metabolism (e.g., estrogens, oral contraceptives, cholestyramine), these may alter thyroid hormone requirements and contribute to fluctuating thyroid status. 7
• Liothyronine produces marked T3 excursions with once-daily dosing, and some patients may benefit from twice-daily divided dosing or a switch to levothyroxine monotherapy for more stable hormone levels. 4

When to Refer to Endocrinology

Refer if hair shedding persists despite normalization of thyroid function tests, if there is difficulty achieving stable thyroid levels, or if the patient has coexisting cardiac disease requiring careful dose titration. 6

• Patients with unusual thyroid function test patterns, suspected malabsorption, or those requiring combination T4/T3 therapy should be managed by an endocrinologist. 6
• Pregnant women or those planning conception should be referred immediately, as thyroid hormone requirements change significantly during pregnancy and TSH targets are trimester-specific. 6

Key Clinical Pitfall to Avoid

Do not dismiss hair shedding as unrelated to liothyronine simply because TSH is "normal" or in the low-normal range. Even subclinical hyperthyroidism (TSH 0.1–0.45 mIU/L) can trigger telogen effluvium, and the absolute T3 level—not just TSH—drives hair follicle dysfunction. 2, 1 Always measure free T3 in addition to TSH when evaluating hair loss in patients on liothyronine. 5, 4